Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is ...

According to the report, treatment with PCSK9 inhibitors generates cost-effectiveness ratios that exceed the commonly-accepted $100,000 per quality-adjusted life year (QALY).

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing ...

The promise of a new era of cholesterol management, heralded by the launch of highly effective PCSK9 inhibitors, has been complicated by significant barriers to uptake of the next-generation products ...

The potential for targeting PCSK9 in people with uncontrollably high cholesterol has not yet been fully realized. When Amgen’s PCSK9 inhibitor Repatha and the rival Sanofi/Regeneron drug ...

The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across ...

MedCo. is a one-drug company whose lead asset, inclisiran, is one of several injectable, cholesterol-lowering meds known as PCSK9 inhibitors. And that’s a drug class with a checkered past. The two ...

Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing Peer-Reviewed Publication Science China Press ...

Between PCSK9 inhibitor and the time of the analysis, median total cholesterol fell from 210 mg/dL to 133 mg/dL, median LDL fell from 125 mg/dL to 53 mg/dL, median non-HDL fell from 158 mg/dL to ...

Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of ...

PCSK9 Inhibitor Prices Should Fall Two-Thirds for Cost-effectiveness: Analysis Larry Hand August 16, 2016 0 ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel target for low-density lipoprotein cholesterol (LDL-C)-lowering therapy, has been found to possess multiple off-target effects in ...